ALX Oncology Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Two novel oncology programs are advancing, with evorpacept showing strong efficacy and safety in HER2-positive cancers and ALX2004 progressing in dose escalation. CD47 overexpression is now a key biomarker, and recent financing supports pivotal milestones through 2028.
-
Two differentiated oncology programs advanced, with Evorpacept showing high response rates in HER2-positive cancers and ALX 2004 progressing in phase I. Aspen breast trial targets a large unmet need post-Enhertu, with interim data expected Q3. Both programs aim for registrational studies by year-end.
Fiscal Year 2025
-
Strong clinical progress in 2025 with Evorpacept and ALX2004, highlighted by robust efficacy in CD47-high cancer patients and a $150M financing extending cash runway through H1 2028. Key data readouts are expected in 2026–2027.
-
Evorpacept’s clinical focus has shifted to anti-cancer antibody combinations, showing strong efficacy in HER2-positive cancers, especially with high CD47 expression. The ALX2004 ADC program is advancing in four tumor types, with safety data expected in H1 2026. Cash runway extends into Q1 2027.
-
The company is advancing two differentiated programs: evorpacept (CD47) and ALX2004 (EGFR ADC), both showing promising early clinical and safety data. Key milestones in 2025 include phase II breast cancer interim results and phase I ADC safety data, supported by a cash runway into 2027.
-
Strong Q3 2025 results highlighted robust efficacy for evorpacept in HER2-positive, CD47 high gastric and breast cancers, and rapid clinical progress for ALX-2004. Cash runway extends into Q1 2027, supporting key milestones in 2026.
-
New ASPEN-06 data validate CD47 as a predictive biomarker for evorpacept, driving a biomarker-focused strategy in HER2-positive cancers. Cash runway now extends to Q1 2027, with key milestones ahead for both evorpacept and ALX-2004.
-
Multiple clinical programs are advancing, including a randomized phase II breast cancer study and a novel EGFR ADC entering phase I. Interim data for breast and colorectal studies are expected in 2026, with strong partnering interest and a cash runway through year-end 2026.
-
ALX 2004, a novel EGFR-targeted ADC, is advancing to phase I trials after robust preclinical data showed strong efficacy and a favorable safety profile. The program targets major unmet needs in EGFR-expressing cancers, with initial safety data expected in 2026.
-
Evorpacept is advancing in multiple oncology indications, with new breast and colorectal trials launching and key data readouts expected in 2025. Aggressive cost management has extended the cash runway into Q4 2026, and a new EGFR-targeted ADC is set to enter the clinic.
-
ASPEN-06 phase II results show evorpacept plus TRP significantly improves response rates and durability in HER2-positive gastric/GEJ cancer, especially in patients confirmed HER2-positive by fresh biopsy or ctDNA. The regimen is well tolerated, and regulatory discussions for accelerated approval are underway.
-
Evorpacept has demonstrated strong efficacy and safety in multiple cancers, with positive phase 2 data in gastric and breast cancer and several major data readouts expected in the first half of the year. Its differentiated dead Fc mechanism enables broad combination strategies and positions it as a leader in the CD47 space.
Fiscal Year 2024
-
Evorpacept plus zanidatamab demonstrated a 55% response rate and strong disease control in heavily pretreated HER2-positive metastatic breast cancer, with a favorable safety profile and durable responses. These results support further development of this chemotherapy-free regimen.
-
Evorpacept, a CD47-targeting agent, is advancing through multiple combination trials in solid and hematologic cancers, showing strong efficacy and safety signals, especially in NHL, bladder, and gastric cancers. Key randomized data in head and neck and breast cancer are expected soon.
-
Key leadership transitions bring deep oncology expertise as multiple pivotal clinical readouts approach. ASPEN-06 gastric study showed strong efficacy in HER2-positive patients, with mature PFS and head and neck data expected in the first half, supported by a solid cash runway.
-
Evorpacept is advancing through multiple late-stage trials in gastric, breast, head and neck, and urothelial cancers, with promising efficacy and safety signals, especially in combination regimens. Key data readouts are expected in 2025, supporting potential accelerated approvals and expansion into new indications.
-
The company is advancing a differentiated CD47 blockade approach, showing strong efficacy and safety in gastric and head and neck cancers, with pivotal data and potential partnerships expected next year. Emphasis on biomarker-driven patient selection is shaping future trials.
-
The ASPEN-06 phase II trial showed that adding evorpacept to TRP significantly improved response rates and durability in HER2-positive gastric cancer, especially in patients with recent HER2-positive biopsies. The combination was well tolerated, and regulatory discussions will guide phase III plans.
-
Evorpacept combined with enfortumab vedotin in advanced bladder cancer showed a 62% overall response rate in a heavily pretreated population, with no dose-limiting toxicities and a favorable safety profile. Durability data are still maturing, and further studies are ongoing to assess long-term benefit and activity in additional patient subgroups.